Is AstraZeneca PLC (AZN) a Buy, Sell, or Hold?
AstraZeneca PLC
NYSE:AZN
$164.5 USD
-$4.97 (-2.93%)
- Volume
- 3.61M
- Average Volume
- 2.14M
- Market Capitalization
- $127.56B
- P/E Ratio
- 24.76
- Dividend Yield
- 1.90%
- Price Target
- $185.00
- Year High
- $212.71
- Year Low
- $137.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.47
- Current Ratio
- $0.91
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Pascal Claude Roland Soriot |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | AZN |
| CUSIP | G0593M107 |
| CIK | 0000901832 |
| Web | https://www.astrazeneca.com |
| Phone | 44 20 3749 5000 |
| Currency | USD |
| Employees | 96100 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.72 |
| Payout Ratio | 0.47 |
| Current Ratio | 0.91 |
| Quick Ratio | 0.71 |
| Cash Ratio | 0.23 |
Sales & Book Value
| Annual Sales | $58.74B |
| Price / Sales | 4.26 |
| Cash Flow | 5.00 |
| Price / Cash Flow | 33.41 |
| Price / Book | 5.46 |
Price Target and Rating
| Average Stock Price Forecast | $185.00 |
| High Stock Price Forecast | $216.00 |
| Low Stock Price Forecast | $158.00 |
| Forecast Upside/Downside | -11.08% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 41 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $13.08 |
| Trailing P/E Ratio | 24.76 |
| PEG Ratio | 0.75 |
| P/E Growth | 0.75 |
| Net Income | $10.26B |
| Net Margin | 17.19% |
| Pretax Margin | 21.37% |
| Return on Equity | 22.41% |
| Return on Assets | 9.17% |
Financials Score
| AltmanZ Score | 2.19 |
| Piotroski Score | 8.00 |
| Working Capital | -2.96B |
| Total Assets | 114.02B |
| Ebit | 14.65B |
| Market Cap | 127.56B |
| Total Liabilities | 66.63B |
Poll Results
About AstraZeneca PLC (NYSE:AZN) Stock
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, A ... frica, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
2026-07-14 16:54:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-07-14 10:12:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on July 9, 2026, after the Company announced that the Phase III CARDIO-TTransform trial of Wainua failed to meet its primary endpoint in ATTR cardiomyopathy. If you held AZN and lost money, you are encouraged to check your eligibility to recover losses now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Solis Minerals launches lithium drilling across 800-metre Mandacaru corridor in Brazil
2026-07-14 07:41:00
Solis Minerals Ltd (ASX:SLM, TSX-V:SLMN, OTCQB:SLMFF) has kicked off diamond drilling at the Mandacaru Lithium Project in Brazil, targeting a coherent...
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
2026-07-14 04:16:00
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal...
ACG Metals beats oxide production target as gold price surges 64%
2026-07-14 03:20:00
ACG Metals Ltd (LSE:ACG, OTC:ACGAF), the London-listed gold, silver and copper group operating the Gediktepe operation in Türkiye, beat its full-year oxide...
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
2026-07-14 03:18:02
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal Pharmaceutical. The Cambridge-based drugmaker could pay a further $900 million if the treatment hits certain development, regulatory and sales targets.
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
2026-07-14 02:55:00
AstraZeneca entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment.
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
2026-07-14 02:19:59
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.
Frequently Asked Questions
-
What is the current AstraZeneca PLC (AZN) stock price?
-
AstraZeneca PLC(NYSE:AZN) stock price is $164.5 in the last trading session. During the trading session, AZN stock reached the peak price of $212.71 while $137.22 was the lowest point it dropped to. The percentage change in AZN stock occurred in the recent session was --2.93% while the dollar amount for the price change in AZN stock was -$-4.97.
-
AZN's industry and sector of operation?
-
The NYSE listed AZN is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of AZN?
-
Lutz Jermutus | Head of Projects
Jeffrey Pott | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Pam Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Ruth March | Senior Vice President of Precision Medicine - R&D Oncology
Iskra Reic | Executive Vice President of International -
How many employees does AZN have?
-
Number of AZN employees currently stands at 96100. AZN operates from 1 Francis Crick Avenue, Cambridge, None CB2 0AA, GB.
-
Link for AZN official website?
-
Official Website of AZN is: https://www.astrazeneca.com
-
How do I contact AZN?
-
AZN could be contacted at phone #44 20 3749 5000 and can also be accessed through its website. AZN operates from 1 Francis Crick Avenue, Cambridge, None CB2 0AA, GB.
-
How many shares of AZN are traded daily?
-
The average number of AZN shares traded daily for last 3 months was 2.14M.
-
What is the market cap of AZN currently?
-
The market value of AZN currently stands at $127.56B with its latest stock price at $164.5